Clinical Research Directory
Browse clinical research sites, groups, and studies.
Intravenous Neonatal Central Access Safety Trial
Sponsor: University of Turin, Italy
Summary
Particulate contamination due to infusion therapy (administration of parenteral nutrition and medications) carries a potential health risk for infants in neonatal intensive care units (NICU). In-line filtration is increasingly used in critically-ill infants but its benefits, by preventing micro-particle infusion in neonates, remain to be demonstrated. In-line filters in the intravenous administration sets prevent the infusion of particles, which may reduce infectious complications.
Official title: Central Lines Filtration in Newborns: a Multicenter Randomized Controlled Trial
Key Details
Gender
All
Age Range
1 Hour - 3 Months
Study Type
INTERVENTIONAL
Enrollment
736
Start Date
2023-01-01
Completion Date
2026-06-30
Last Updated
2026-03-30
Healthy Volunteers
No
Interventions
In-line filter
All infusions, with the exception of some solutions (eg blood products), will be subjected to filtration. The aqueous solutions (parenteral therapy and drugs) will be administered through 0.2 μm filters which will be replaced every 96 h; the lipid emulsions will be administered through 1.2 μm filters which will be replaced every 24 h. In case of emergency, life-saving drugs will be administered with bolus modality though the infusion line closer to the patient without the need for filtration. In case of drugs/solutions not supported by filtration (eg blood products), they will be administered through a dedicated unfiltered access, which will be removed as soon as the drug is no longer needed.
Locations (1)
Città della Salute e della Scienza
Torino, Italia, Italy